HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Biotech Stock With Strong Fundamentals and Attractive Valuation

Last update: Jun 3, 2025

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) was identified by our stock screener as a potential value opportunity in the biotechnology sector. The company combines strong profitability and financial health with an attractive valuation, making it worth a closer look for investors seeking undervalued stocks with solid fundamentals.

Valuation Highlights

Price/Earnings (P/E) Ratio: HALO trades at a P/E of 12.23, significantly below both the industry average (58.00) and the S&P 500 average (26.29).
Price/Forward Earnings: At 7.95, this suggests HALO is priced attractively compared to future earnings expectations.
Enterprise Value/EBITDA: The company’s EV/EBITDA ratio is cheaper than 96.59% of its industry peers.
Price/Free Cash Flow: HALO’s valuation is favorable, with 95.70% of biotech firms trading at higher multiples.

Financial Health

Strong Solvency: HALO has an Altman-Z score of 4.70, indicating low bankruptcy risk.
Liquidity: Current and Quick Ratios of 8.39 and 7.30, respectively, demonstrate ample short-term financial flexibility.
Debt Management: While the Debt/Equity ratio is elevated at 3.13, the company has reduced its debt/assets ratio over the past year.

Profitability

High Margins: Operating Margin (55.10%) and Gross Margin (83.45%) rank among the best in the industry.
Strong Returns: Return on Equity (100.64%) and Return on Invested Capital (23.44%) outperform most peers.
Consistent Earnings: HALO has been profitable for five consecutive years with positive cash flow.

Growth Prospects

Past Growth: Revenue and EPS have grown at annualized rates of 38.95% and 30.12%, respectively.
Future Expectations: Analysts project EPS growth of 16.06% and revenue growth of 11.27% annually.

Our Decent Value Stocks screener lists more stocks with similar characteristics.
For a deeper analysis, review the full fundamental report on HALOZYME THERAPEUTICS.

Disclaimer

This is not investment advice. The observations are based on data available at the time of writing. Always conduct your own research before making investment decisions.